Research and Development Division, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
Phytomedicine. 2010 Dec 15;18(1):11-5. doi: 10.1016/j.phymed.2010.09.001. Epub 2010 Oct 29.
We have investigated the potential in vivo anti-tumour activity of corilagin using the Hep3B hepatocellular carcinoma cell line and an athymic nude mice xenograft model. The purity of corilagin was confirmed by high performance liquid chromatographic analysis. Corilagin was administrated intraperitoneally for a continuous period of 7 days at a concentration of 15 mg/kg of body weight per day. A significant inhibition of tumour growth was observed when treated mice are compared with control groups. Furthermore, analysis of enzymes markers of liver function, including alanine aminotransferase and asparate aminotransferase, suggested that current therapeutic dosage of corilagin did not exert adverse effect on liver. Our observations support the view that corilagin is considerably effective to retard the in vivo growth of xenografted Hep3B hepatocellular carcinoma.
我们使用 Hep3B 肝癌细胞系和裸鼠异种移植模型研究了柯里拉京的体内抗肿瘤活性。通过高效液相色谱分析证实了柯里拉京的纯度。柯里拉京以 15mg/kg/天的剂量每天腹腔注射连续 7 天。与对照组相比，接受治疗的小鼠的肿瘤生长明显受到抑制。此外，对肝功能酶标志物，包括丙氨酸氨基转移酶和天冬氨酸氨基转移酶的分析表明，柯里拉京的当前治疗剂量对肝脏没有不良影响。我们的观察结果支持柯里拉京能够显著抑制异种移植 Hep3B 肝癌在体内生长的观点。
